Paclitaxel eluting balloon: from bench to bedside.
Despite the impressive progress of percutaneous treatment modalities, restenosis remains the major Achilles heel of interventional cardiology. Approximately 25% of the general population treated for coronary diseases with a bare-metal stent and about 10% of patients treated with a drug-eluting stent develop an overgrowth of vascular tissue and renarrowing inside the stent, or in-stent restenosis. These rates are even greater in diabetics and patients at higher risk of restenosis both for clinical presentation (patients in dialysis, low ejection fraction) or anatomical characteristics (ostial, bifurcation, long lesions). Non-stent based local drug delivery and particularly the use of paclitaxel eluting balloon (PEB) could be one promising strategy to reduce restenosis. This review will briefly explore the different characteristics of PEB devices currently present in the market and summarize the results obtained both in animal models and clinical practice, giving an indication of the potential field of application of this new technology.
Marzullo
R
R
Department of Cardiology, Policlinic of Modena, Modena, Italy.
Aprile
A
A
Clementi
F
F
Stella
P
P
Modena
M G
MG
Sangiorgi
G M
GM
D000818:Animals; D002404:Catheterization / Q000295:instrumentation* / Q000639:trends; D023903:Coronary Restenosis / Q000517:prevention & control*; D054855:Drug-Eluting Stents; D005544:Forecasting; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage*; D019736:Prostheses and Implants
D017239:Paclitaxel